Administration of pentoxifylline during allergen sensitization dissociates pulmonary allergic inflammation from airway hyperresponsiveness

Journal of Immunology

Volumn 167, Issue 3, 2001, Pages 1703-1711

  Fleming, C M ^a   He, H ^a   Ciota, A ^a   Perkins, D ^a   Finn, P W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGEN; CYTOKINE; GAMMA INTERFERON; IMMUNOGLOBULIN E; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 4; OVALBUMIN; PENTOXIFYLLINE;

AIRWAY OBSTRUCTION; ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRONCHUS HYPERREACTIVITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; IMMUNOGLOBULIN BLOOD LEVEL; LUNG LAVAGE; MOUSE; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; TH1 CELL; TH2 CELL;

EID: 0035425244     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.3.1703     Document Type: Article

References (90)

1. Immune mechanisms of childhood asthma
2. Requirement for IL-13 independently of IL-4 in experimental asthma
3. Interleukin-13: Central mediator of allergic asthma
4. Inhibitory effects of endogenous and exogenous interferon-γ on bronchial hyperresponsiveness, allergic inflammation and T-helper 2 cytokines in Brown-Norway rats
5. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production
6. Anti-inflammatory actions of interleukin-13: Suppression of tumor necrosis factor-α and antigen-induced leukocyte accumulation in the guinea pig lung
7. Development of airway hyperresponsiveness is dependent on interferon-gamma and independent of eosinophil infiltration
8. T-cell cytokine profile evaluated at the single cell level in BAL and blood in allergic asthma
9. TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma
10. Blockade of CD28/B7 interaction suppresses allergic eosinophilic inflammation in mice
11. Preferential role for NF-κB/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo
12. New insights into the roles of ReL/NF-κB transcription factors in immune function, hemopoiesis and human disease
13. New insights into the role of nuclear factor-κB, a ubiquitous transcription factor in the initiation of diseases
14. Nuclear factor-κB
15. Transcription factors as activators of gene transcription: AP-1 and NF-κB
16. The role of nuclear factor-κB in cytokine gene regulation
17. Activation and localization of transcription factor, nuclear factor-κB, in asthma
18. Differential regulation of IFN-γ, IL-10 and inducible nitric oxide synthase in human T cells by cyclic AMP-dependent signal transduction pathway
19. Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells
20. Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: An effect of the novel anti-inflammatory drug lisofylline
21. Selective pharmacologic inhibition of murine and human IL-12-dependent Th1 differentiation and IL-12 signaling
22. Relationship between the clinical efficacy of pentoxifylline treatment and elevation of serum T helper type 2 cytokine levels in patients with human T-lymphotropic virus type 1-associated myelopathy
23. The effect of pentoxifylline (PTX) on Theiler's murine encephalomyelitis (TMEV)-induced demyelinating disease
24. Oxpentifylline inhibits tumor necrosis factor-alpha mRNA transcription and protects against arthritis in mercuric chloride-treated brown Norway rats
25. The phosphodiesterase inhibitors pentoxifylline and rolipram prevent diabetes in NOD mice
26. Inhibition of human interleukin-12 production by pentoxifylline
27. Pentoxifylline, a phosphodiesterase inhibitor, induces immune deviation in patients with multiple sclerosis
28. Synergistic immunomodulatory effects of interferon-β1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis
29. Pentoxifylline delays the onset of experimental allergic encephalomyelitis in mice by modulating cytokine production in peripheral blood mononuclear cells
30. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1-but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats
31. Cooperative inhibition of NF-κB and Tat-induced superactivation of human immunodeficiency virus type 1 long terminal repeat
32. Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-κB action
33. Expression of a constitutive NF-κB-like activity is essential for proliferation of cultured bovine vascular smooth muscle cells
34. Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity
35. Activation of NFκB is essential but not sufficient to stimulate mitogenesis of vascular smooth muscle cells
36. c-Rel is a target of pentoxifylline-mediated inhibition of T lymphocyte activation
37. Pentoxifylline for the treatment of HIV infection and its complications
38. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma
39. T cell activation in a murine model of asthma
40. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography
41. Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis
42. Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model
43. Rapid detection of octamer binding proteins with "mini-extracts," prepared from a small number of cells
44. NF-κB/Rel transcription factors: c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation
45. Interferon γ regulates binding of two nuclear protein complexes in a macrophage cell line
46. Essential role of nuclear factor κB in the induction of eosinophilia in allergic airway inflammation
47. Pentoxifylline: Its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice
48. Distribution and metabolism of pentoxifylline in non-tumor-bearing mice
49. Phosphodiesterase isozymes: Molecular targets for novel antiasthma agents
50. The effect of selective phosphodiesterase inhibitors in comparison with other anti-asthma drugs on allergen-induced eosinophilia in guinea-pig airways
51. Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs
52. Inhibition of antigen-induced pulmonary eosinophilia and neutrophilia by selective inhibitors of phosphodiesterase types 3 or 4 in Brown Norway rats
53. Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs
54. Effects of inhibitors of phosphodiesterase, on antigen-induced bronchial hyperreactivity in conscious sensitized guinea-pigs and airway leukocyte infiltration
55. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram
56. Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase type IV inhibitor
57. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4
58. Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats
59. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs
60. Effect of aerosolized administration of KF19514, a phosphodiesterase 4 inhibitor, on bronchial hyperresponsiveness and airway inflammation induced by antigen inhalation in guinea-pigs
61. Studies on anti-allergic action of AH 21-132, a novel isozyme-selective phosphodiesterase inhibitor in airways
62. Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits
63. Suppression of anti-CD3-induced interleukin-4 and interleukin-5 release from splenocytes of Mesocestoides corti-infected BALB/c mice by phosphodiesterase 4 inhibitors
64. Regulation of interleukin- 13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones
65. Differential efficacy of lymphocyte- and monocyte-selective pretreatment with a type 4 phosphodiesterase inhibitor on antigen-driven proliferation and cytokine gene expression
66. In vitro down-regulation of antigen-induced IL-5 gene expression and protein production by cAMP-specific phosphodiesterase type 4 inhibitor
67. Phosphodiesterase inhibitors suppress proliferation of peripheral blood mononuclear cells and interleukin-4 and -5 secretion by human T-helper type 2 cells
68. Effect of phosphodiesterase inhibition on IL-4 and IL-5 production of the murine TH2-type T cell clone D10.G4.I
69. The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents
70. Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases
71. Histamine potently suppresses human IL-12 and stimulates IL-10 production via H2 receptors
72. Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram
73. Allergy and asthma: Classic TH2 diseases (?)
74. Th1/Th2 lymphocyte polarization in asthma
75. Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma
76. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3
77. The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by interleukin-5
78. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness
79. Development of eosinophilic airway inflammation and airway hyperresponsiveness requires interleukin-5 but not immunoglobulin E or B lymphocytes
80. Role of the Th2 cytokines in the development of allergen-induced airway inflammation and hyperresponsiveness
81. IL-5 and eosinophils are essential for the development of airway hyperresponsiveness following acute respiratory syncytial virus infection
82. Interleukin-13: Central mediator of allergic asthma
83. Requirement for IL-13 independently of IL-4 in experimental asthma
84. Functional diversity of helper T lymphocytes
85. IL-13 expression as the sites of allergen challenge in patients with asthma
86. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: Relationship to interleukin-4 and eosinophil counts
87. Cytokine profiles of BAL T cells and T-cell clones obtained from human asthmatic airways after local allergen challenge
88. Dissociation of airway responsiveness and bronchoalveolar lavage (BAL) cell composition in sensitized guinea-pigs after daily inhalation of ovalbumin
89. Dissociation of airway hyperresponsiveness from immunoglobulin E and airway eosinophilia in a murine model of allergic asthma
90. Effects of interleukin 5-induced pulmonary eosinophilia on airway reactivity in the guinea pig